Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Chambers Michael Andrew, Director. Director active across 1 company, notably Sarepta Therapeutics, Inc.. Cumulatively, 11 disclosures have been logged. Split: 6 buys · 0 sell. Total volume traded: €11.2m. Activity tracked since 2 June 2022. The latest transaction was filed on 16 August 2024 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Michael Andrew Chambers is a Board Member at Sarepta Therapeutics, Inc., a biopharmaceutical company focused on developing treatments for rare diseases. As a board member, he participates in overseeing the company's strategies and making key decisions. Michael brings expertise in biopharmacy and product development.